Quick Answer
Oruka Therapeutics, Inc. reported Operating Income Loss of -$122.05 million for the year ending 2025.
- Oruka Therapeutics, Inc. showed a decrease of -38.5% in Operating Income Loss from 2024 to 2025.
- This data is from Oruka Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: -$1.70 million | Q3 2011: -$1.82 million | Q1 2012: -$1.41 million | Q2 2012: -$1.15 million | Q3 2012: -$928.0 thousand | Q1 2013: -$1.07 million | Q2 2013: -$1.20 million | Q3 2013: -$1.73 million | Q1 2014: -$2.39 million | Q2 2014: -$2.41 million | Q3 2014: -$2.29 million | Q1 2015: -$2.74 million | Q2 2015: -$2.72 million | Q3 2015: -$2.82 million | Q1 2016: -$3.67 million | Q2 2016: -$3.94 million | Q3 2016: -$4.71 million | Q1 2017: -$4.38 million | Q2 2017: -$5.56 million | Q3 2017: -$4.48 million | Q1 2018: -$2.77 million | Q2 2018: -$2.16 million | Q3 2018: -$1.66 million | Q1 2019: -$1.78 million | Q2 2019: -$1.51 million | Q3 2019: -$1.25 million | Q1 2020: -$1.34 million | Q2 2020: -$1.31 million | Q3 2020: -$1.99 million | Q1 2021: -$4.10 million | Q2 2021: -$4.84 million | Q3 2021: -$4.72 million | Q1 2022: -$3.28 million | Q2 2022: -$3.22 million | Q3 2022: -$2.55 million | Q1 2023: -$1.80 million | Q2 2023: -$1.97 million | Q3 2023: -$1.94 million | Q1 2024: -$6.86 million | Q2 2024: -$21.49 million | Q3 2024: -$29.45 million | Q1 2025: -$25.09 million | Q2 2025: -$28.43 million | Q3 2025: -$34.11 million.
- Over the full 16 years of available data (2010 to 2025), Oruka Therapeutics, Inc.'s Operating Income Loss has declined by 1,230.3%.
- Historical annual values: Fiscal year 2025: -$122.05 million | Fiscal year 2024: -$88.12 million | Fiscal year 2023: -$7.30 million | Fiscal year 2022: -$10.60 million | Fiscal year 2021: -$19.34 million | Fiscal year 2020: -$9.77 million | Fiscal year 2019: -$5.81 million | Fiscal year 2018: -$8.12 million | Fiscal year 2017: -$18.71 million | Fiscal year 2016: -$16.61 million | Fiscal year 2015: -$11.46 million | Fiscal year 2014: -$9.69 million | Fiscal year 2013: -$6.94 million | Fiscal year 2012: -$4.32 million | Fiscal year 2011: -$7.36 million | Fiscal year 2010: -$9.18 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: